Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Selective Trial Of Paxlovid for PASC (STOP-PASC): Randomized Double-Blind Placebo-Controlled Pilot Trial of Paxlovid for the Treatment of PASC

NCT05576662 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT05576662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05576662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Selective Trial Of Paxlovid for PASC (STOP-PASC): Randomized Double-Blind Placebo-Controlled Pilot Trial of Paxlovid for the Treatment of PASC
Lead sponsor
Stanford University
Phase
Phase 2
Overall status
Completed
Start date
November 8, 2022
Completion date
September 12, 2023
Enrollment
168 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

long covid, post-acute sequelae of sars-cov-2 infection